Full Text View
Tabular View
No Study Results Posted
Related Studies
Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency
This study has been completed.
Study NCT00011141   Information provided by National Center for Research Resources (NCRR)
First Received: February 12, 2001   Last Updated: June 23, 2005   History of Changes

February 12, 2001
June 23, 2005
 
 
 
 
Complete list of historical versions of study NCT00011141 on ClinicalTrials.gov Archive Site
 
 
 
Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency
Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency

The etiology of immune-mediated diabetes mellitus (IMD) remains unclear. However, previous studies indicate that autoimmunity may be a result of dysfunction of natural killer T cells (NK-T cells). Newly diagnoses patients with IMD have been shown in our laboratory to have significantly lower NK-T cells than normal controls. Other studies have shown that oral administration of lactobacillus can boost NK-T cell activity in children with HIV without side effects. Our objective is to evaluate the effect of lactobacillus administration on NK-T cell activity in patients with IMD

 
 
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Diabetes Mellitus
Drug: Oral lactobacillus administration
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
 
 

Recently diagnosed (within the last 6 months) patients with immune-mediated (type 1) diabetes

Both
1 Year to 95 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00011141
 
NCRR-M01RR06020-0165
National Center for Research Resources (NCRR)
 
 
National Center for Research Resources (NCRR)
December 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP